{"id":"NCT02810444","sponsor":"Biotest","briefTitle":"Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID","officialTitle":"An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-04","primaryCompletion":"2020-04-01","completion":"2020-04-01","firstPosted":"2016-06-23","resultsPosted":"2023-07-12","lastUpdate":"2023-07-20"},"enrollment":81,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Disease"],"interventions":[{"type":"BIOLOGICAL","name":"IgG Next Generation (BT595)","otherNames":["Immune Globulin Intravenous (Human), 10% Liquid"]}],"arms":[{"label":"BT595","type":"EXPERIMENTAL"}],"summary":"This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)","primaryOutcome":{"measure":"Rate of Acute Serious Bacterial Infections","timeFrame":"approx. 12 month treatment period","effectByArm":[{"arm":"BT595","deltaMin":0.015,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States","Germany","Hungary","Russia","Spain"]},"refs":{"pmids":["35944615","36383294"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":67},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Bronchitis","Sinusitis"]}}